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Natural killer T (NKT) cells are distinct glycolipid reactive innate lymphocytes that are 
implicated in the resistance to pathogens and tumors. Earlier attempts to mobilize NKT cells, 
specifically, in vivo in humans met with limited success. Here, we evaluated intravenous 
injection of monocyte-derived mature DCs that were loaded with a synthetic NKT cell 
ligand, 
 
 
 
-galactosyl-ceramide (
 
 
 
-GalCer; KRN-7000) in five patients who had advanced 
cancer. Injection of 
 
 
 
-GalCer–pulsed, but not unpulsed, dendritic cells (DCs) led to 
 
 
 
100-
fold expansion of several subsets of NKT cells in all patients; these could be detected for up 
to 6 mo after vaccination. NKT activation was associated with an increase in serum levels of 
interleukin-12 p40 and IFN-
 
 
 
 inducible protein-10. In addition, there was an increase in 
memory CD8
 
 
 
 T cells specific for cytomegalovirus in vivo in response to 
 
 
 
-GalCer–loaded 
DCs, but not unpulsed DCs. These data demonstrate the feasibility of sustained expansion of 
NKT cells in vivo in humans, including patients who have advanced cancer, and suggest that 
NKT activation might help to boost adaptive T cell immunity in vivo.
 
Immune recognition of pathogens and tumors
involves innate and adaptive arms of the immune
system. NKT cells are innate lymphocytes that
are implicated in the control of autoimmunity,
and resistance to tumors and pathogens (1, 2).
In contrast with conventional CD4/CD8
 
 
 
 T
cells that recognize peptide antigens, NKT cells
respond to glycolipid ligands in the context of
CD1d (2). 
 
 
 
-galactosyl-ceramide (
 
 
 
-GalCer),
first isolated from a marine sponge, is a syn-
thetic ligand that is presented effectively on
CD1d molecules to human and murine NKT
cells (3). Activation of NKT cells in mice by
injection of 
 
 
 
-GalCer is associated with a rapid
release of cytokines within hours. Stimulation
of NKT cells is followed by downstream acti-
vation of NK cells, DCs, and T cells (4–7).
 
 
 
-GalCer–mediated NKT activation was shown
to mediate tumor regression in several mouse
models. The antitumor effects of NKT cells are
due to several mechanisms, including enhance-
ment of immune effectors and antiangiogenesis
(8–13). NKT cells also contribute to resistance
against spontaneous and carcinogen-induced
tumors in mice (13–15).
Human NKT cells have been analyzed on
the basis of their expression of an invariant T
cell receptor (V
 
 
 
24/V
 
 
 
11) and their binding
to CD1d-
 
 
 
-GalCer multimers (16). Human
V
 
 
 
24
 
 
 
 NKT cells can mediate antitumor effects
in vitro; a deficiency of NKT cells, or defects in
their function, were described in cancer pa-
tients (9, 17–19). The availability of 
 
 
 
-GalCer
as the pharmaceutical-grade drug, KRN-7000
(Kirin Breweries), has led to attempts to boost
NKT cells in vivo in patients who had ad-
vanced cancer or healthy volunteers. How-
ever, the injection of KRN-7000 alone, or
KRN-7000–loaded immature DCs, only leads
to transient NKT activation in some individu-
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als (20, 21). In previous studies, we observed that mature
DCs are superior to immature DCs for activating human
NKT cells in vitro (22). Here, we studied the immune re-
sponses to injection of KRN-7000–loaded mature DCs in
patients who had advanced cancers.
 
RESULTS
Clinical characteristics
 
Six eligible patients were enrolled in this trial. One of the
patients was removed from the study before receiving any
 
 
 
-GalCer–loaded DCs to explore other options for progres-
Figure 1. Expansion of NKT cells after injection of GalCer-pulsed 
DCs. (A) Kinetics of V 24 /V 11  NKT cells in blood. The proportion of 
V 24 /V 11  NKT cells in blood was monitored before and after DC 
vaccination. The dates of DC injections are depicted by arrows. (B) Repre-
sentative FACS plots showing the number of invariant NKT cells before 
and after DC vaccination. Numbers in upper right quadrant represent 
percentage of NKT/total lymphocytes. (C) Correlation between kinetics of 
 -GalCer dimer binding cells and invariant TCR  cells. Dimer positive 
NKT cells were analyzed based on the coexpression of V 24 or V 11. The 
data shown are from K3. (D) Representative FACS plots showing the ex-
pression of V 24/V 11  on  -GalCer–CD1d dimer binding cells elicited 
after vaccination in a patient (K3). A sub-population of V 24-CD1d 
dimer  cells is circled. Note that the V 11  dimer  populations consist 
of two distinct subsets. (E) Expansion of invariant NKT cells in the tumor 
bed. NKT cells in the blood or marrow tumor bed were monitored by 
flow cytometry. 
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Figure 1 (continued)
 
sive tumor. This paper describes the results with the first five
patients who received the entire set of three vaccines. Patient
characteristics are shown in Table I. All had received exten-
sive therapy for their cancers with persistent disease; three of
five patients had objective evidence of progressive disease at
study entry. The characteristics of the DC preparations are 
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shown in Table II. All DC preparations met release criteria
and postrelease testing.
 
Toxicity
 
The DC injections were well-tolerated in all patients with
no greater than grade 1 injection-related toxicity (Table II).
One patient developed rheumatoid factor (RF) and transient
positive antinuclear antibody (ANA) at follow-up testing 1
mo after the third injection. This patient also incidentally
was noted to have an increase in activated partial thrombo-
plastin time after vaccination which was believed to be sec-
ondary to an inhibitor. There was no clinical evidence of au-
toimmunity or hepatic toxicity in any patient.
 
NKT activation and expansion
 
None of the patients had detectable circulating NKT cells at
baseline, which was likely due to extensive therapy of the
underlying malignancy. The injection of unpulsed DCs did
not lead to an increase in NKT cells in any patient at any
time point. In contrast, the injection of 
 
 
 
-GalCer–pulsed
DCs led to 
 
 
 
100-fold increase in circulating NKT cells in
all patients (Fig. 1 A). This was detectable as an increase in
cells that were positive for invariant TCR and 
 
 
 
-GalCer–
CD1d dimer binding (Fig. 1, B–D). NKT cells peaked at
7–30 d after vaccination and already were increased after the
first injection of 
 
 
 
-GalCer–pulsed DCs in four of five pa-
tients. The numbers of NKT cells stayed above baseline for
 
Table I.
 
Patient characteristics
 
Patient
ID Age Sex Diagnosis Stage Previous  therapy
Disease status
at entry
Disease
at study entry
Best response
on study
Duration
on study
Current
status
 
yr mo
 
K-1 62 M myeloma III chemotherapy,
stem cell transplant
progressive urine M spike
3.3 g/d
urine M spike
3.0 g/d
9 alive
K-2 41 M myeloma III chemotherapy,
stem cell transplant
stable serum M spike
1.0 g/dl
serum M spike
0.4 g/dl
10 alive
K-3 57 M anal cancer
(squamous cancer)
IV radiation, 
chemotherapy, surgery
progressive metastases to liver,
peritoneum
none 4 deceased
K-4 70 M renal cell cancer IV surgery, IFN, TK inhibitor progressive metastases to lung,
adrenal
stable metastatic
disease
8
 
 
 
alive
K-5 63 M myeloma III radiation, chemotherapy,
stem cell transplant
stable urine M spike
116 mg/d
urine M spike
79 mg/d
10
 
 
 
alive
 
Table II.
 
Characteristics of dendritic cells
 
Patient ID DC injection no.  Dose Viability Purity  Maturity Injection-related toxicity
 
10
 
6
 
 cells % CD83
 
 
 
K-1 1 (unpulsed DCs) 5 100 83 94 fever (grade 1)
K-1 2 (KRN-7000 pulsed DCs) 5 99 83 94 none
K-1 3 (KRN-7000 pulsed DCs) 5 99 61 90 none
K-2 1 (unpulsed DCs) 5 100 52 94 none
K-2 2 (KRN-7000 pulsed DCs) 5 98 58 83 none
K-2 3 (KRN-7000 pulsed DCs) 5 99 53 89 none
K-3 1 (unpulsed DCs) 5 99 95 86 none
K-3 2 (KRN-7000 pulsed DCs) 5 96 92 66 none
K-3 3 (KRN-7000 pulsed DCs) 5 97 90 67 none
K-4 1 (unpulsed DCs) 5 100 86 93 none
K-4 2 (KRN-7000 pulsed DCs) 5 99 80 93 none
K-4 3 (KRN-7000 pulsed DCs) 5 98 89 94 ANA, RF positive;
increase in aPTT due to inhibitor
K-5 1 (unpulsed DCs) 5 99 82 87 rash (grade 1)
K-5 2 (KRN-7000 pulsed DCs) 5 100 81 94 none
K-5 3 (KRN-7000 pulsed DCs) 5 100 80 92 none
 
aPTT, activated partial thromboplastin time. 
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84 d in all patients, and were elevated above baseline for
 
 
 
6 mo in two patients with longer follow-up. There was a
transient decline in circulating NKT cells on day 1 after
 
 
 
-GalCer–pulsed DC injection. This decline was not due to
TCR down-regulation, because the number of intracellular
TCR
 
 
 
 cells also was monitored and closely followed cell
surface staining (unpublished data). Earlier studies in mice
that showed TCR down-regulation in NKT cells after in-
jection of 
 
 
 
-GalCer monitored splenic, but not blood, NKT
cells, as measured here (23). In one patient who had my-
eloma, we looked for NKT cells in the marrow tumor bed
before and after DC vaccination, and we could demonstrate
sustained expansion of invariant NKT cells there for 
 
 
 
3 mo
after vaccination (Fig. 1 E). Thus, injection of 
 
 
 
-GalCer–
loaded DCs leads to a sustained increase in NKT cells in
blood and the tumor bed.
 
Phenotype of NKT cells expanded in vivo
 
Recent studies showed that the subset of cells that binds to
 
 
 
-GalCer–loaded CD1d tetramers can include invariant
TCR
 
 
 
 and invariant TCR
 
 
 
 cells (24). In one study, many
of the V
 
 
 
24
 
 
 
, tetramer
 
 
 
 cells were V
 
 
 
11
 
 
 
, which suggests
alternate V
 
 
 
 TCR usage by the CD1d multimer
 
 
 
 cells (24).
The kinetics of increase in CD1d-glycolipid dimer
 
 
 
 and
V
 
 
 
24/V
 
 
 
11
 
 
 
 cells in all patients were matched closely (Fig.
1, C and D). However, the numbers of dimer
 
 
 
/V
 
 
 
11
 
 
 
 cells
generally exceeded the numbers of V
 
 24/V 11  cells, or
dimer V 24  cells. Indeed, the expansion of dimer /
V 24  populations also could be demonstrated by flow cy-
tometry (Fig. 1 D). Therefore, DC vaccination led to in-
creases in dimer V 24  and dimer V 24 NKT cells in
vivo, with similar kinetics.
Recent studies showed that human NKT cells consist of
functionally distinct subsets that are based on the expression of
CD4/CD8 (25, 26). In two patients who had postvaccination
frequency of  103 NKT cells/106 PBMCs (K2, K3), the pro-
portion of NKT subsets was analyzed by flow cytometry. In
both patients, the phenotype of expanded invariant TCR 
cells was predominantly CD4  at the early time points; how-
ever, at later time points, we noted an increase in double neg-
ative and CD8  NKT cells (Fig. 2, A and B). Thus, DC-medi-
ated mobilization of NKT cells in humans is associated with
expansion of all three human NKT subsets in circulation,
which may, however, have different kinetics of mobilization.
Changes in serum cytokines
 -GalCer–mediated NKT activation in vivo can lead to
changes in serum cytokines in mice (10). However, changes
in serum cytokines also can occur as a result of DC vaccina-
tion alone and changes in the underlying disease. To distin-
guish these effects from those that are specifically due to
 -GalCer–mediated activation, we analyzed paired serum
samples before and 24 h after each vaccine for 20 cytokines/
chemokines using a cytokine multiplex method. Changes in
the serum levels after  -GalCer–pulsed DCs for each cyto-
kine in each patient were analyzed in the context of the
changes after unpulsed DCs as a control. The sera from one
patient (K4, who also developed ANA/RF positivity after
vaccine; Table I) showed a high background from baseline
and postvaccine samples that was consistent with autoim-
mune phenotype and were not analyzable by this method.
The following cytokines were analyzed in this assay: IL-1 ,
-2, -4, -5, -6, -8, -10, -12 p40, -13, -15, -17; IFN- ; TNF- ;
GM-CSF; macrophage inflammatory protein (MIP)-1 
and -1 ; IFN- –inducible protein (IP)-10; monocyte che-
moattractant protein-1; eotaxin; and regulated on activation,
normal T cell expressed and secreted. Of this panel, three
cytokines (IL-12 p40, IP-10, MIP-1 ) consistently showed
Figure 2. Kinetics of NKT subsets after the injection of  -GalCer–
pulsed DCs. (A) Proportion of CD4 , double negative (DN) or CD8  subsets 
of NKT cells after  -GalCer/DC vaccination in two patients (K2 and K3), as 
analyzed by flow cytometry. (B) Representative FACS plots from a patient (K2), 
showing subsets of mobilized NKT cells, at early, mid or later time points, as 
shown in (A). In the lower panel, numbers in the upper right quadrant are 
percentage of CD4 /double negative/CD8 , respectively of total NKT cells.DC-MEDIATED NKT ACTIVATION IN CANCER | Chang et al. 1508
a statistically significant increase after injection of  -GalCer–
loaded DCs (third vaccine), but not unpulsed DCs (first vac-
cine) in all subjects tested (Fig. 3, A–C). Similar findings
were noted when first and second vaccines were compared
(unpublished data). This, coupled with a transient, but
 -GalCer–specific decline in circulating NKT cell numbers
on day 1 (Fig. 1 A), suggests in vivo NKT activation and
homing to tissues with IFN-  release in situ; this accounts
for an increase in IP-10. The other two cytokines (IL-12
and MIP-1 ) were likely to be released in vivo by antigen-
presenting myeloid cells (27, 28).
Cytokine production by in vivo expanded circulating NKT cells
Circulating NKT cells from healthy humans respond to
 -GalCer with rapid production of IFN-  in vitro (29). As
DC vaccination led to an increase in NKT cells to within the
range that is seen in healthy donors, we analyzed the ability of
these cells to secrete IFN-  in vitro using Elispot and intra-
cellular cytokine secretion (ICS). In both assays, freshly iso-
lated NKT cells that were mobilized in vivo produced little
detectable IFN- , with the exception of some time points in
one patient (K3; Fig. 4, A and B). Therefore, freshly isolated
circulating NKT cells expanded in vivo seemed to be im-
paired in their ability to secrete IFN- , similar to that re-
ported for naturally occurring NKT cells in patients who had
myeloma and other advanced cancers (17, 19).
A lack of IFN-  production may be associated with the
production of other cytokines. For example, in mice, IL-13–
producing NKT cells have immune regulatory properties
(30). Therefore, production of alternate cytokines was ana-
lyzed by two methods. An analysis of supernatants from
overnight cultures of PBMCs before and after vaccination
confirmed the lack of increase in IFN-  or the chemokine,
IP-10 (normally produced in response to IFN- ; unpub-
lished data). No increase in IL-4, -10, -13, and -2 was noted
in these supernatants (unpublished data). RNA that was iso-
lated from these cells also was analyzed for IFN- , IL-4, and
IL-13 transcripts by TaqMan, and again confirmed the data
from other assays (unpublished data). Therefore, NKT cells
that were mobilized in vivo in blood after  -GalCer DC in-
jection were less efficient at rapid IFN-  production in re-
sponse to  -GalCer restimulation in short-term assays, com-
pared with those from healthy donors.
Proliferative capacity of mobilized NKT cells
Human NKT cells readily undergo several fold expansion in
vitro after stimulation with  -GalCer–pulsed mature DCs to
yield NKT cells with a Th1 phenotype. To test the prolifer-
ative capacity of mobilized NKT cells, pre- and postimmu-
nization PBMCs were cultured with  -GalCer–loaded DCs.
Minimal NKT expansion was seen in preimmunization sam-
ples, which was consistent with a severe deficiency of NKT
cells at baseline. In contrast, NKT cells could be expanded
readily from postvaccine samples in just 1-wk cultures (Fig. 5
A). The expanded NKT cells again were V 24 / -GalCer–
dimer  and V 24 / -GalCer–dimer , as in the case of
freshly isolated NKT cells (Fig. 5 B). Even when these ex-
panded NKT cells were stimulated in vitro with  -GalCer–
loaded DCs, they exhibited reduced capacity for IFN-  se-
cretion when compared with their counterparts from healthy
Figure 3. Cytokine multiplex analysis. Increase or decrease in serum 
levels before and 24 h after unpulsed (first DC injection) or  -GalCer–
pulsed DC vaccine (third DC injection) were analyzed separately for each 
patient by Luminex. (A) Changes in serum IL-12p40. (B) Changes in serum 
MIP-1 . (C) Changes in serum IP-10.JEM VOL. 201, May 2, 2005 1509
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controls (Fig. 5 C). This was confirmed again by TaqMan
analysis, wherein the  -GalCer–reactive increase in IFN- 
was significantly lower in patients versus healthy controls
(Fig. 5 D).
Activation of adaptive T cell immunity: changes in 
virus-specific memory T cells
The increase in serum IL-12 after  -GalCer/DC vaccination
suggested the possibility that NKT activation might lead to
the activation of APCs in vivo, which, in turn, might en-
hance antigen-specific CD8  killer T cell responses (31–33).
To assess changes in antigen-specific T cells, viral anti-
gen-specific T cells against influenza matrix protein and
CMVpp65 were monitored by Elispot and MHC tetramers.
This was feasible because all patients were HLA A2 . An in-
crease in CMVpp65-specific, but not influenza matrix pep-
tide (Flu-MP)–specific IFN-  producers in fresh PBMCs was
observed in three of four patients who were tested following
the injection of  -GalCer–pulsed, but not unpulsed, DCs
(Fig. 6 A). This also was accompanied by a modest increase in
peptide-MHC tetramer binding cells (unpublished data). To
assess memory T cells, PBMCs from before and after immu-
nization were thawed together and expanded using peptide-
loaded DCs. Antigen-specific T cell expansion was moni-
tored using MHC tetramers. Injection of  -GalCer–loaded
DCs was associated with a significant increase in CMV-spe-
cific memory T cells—but not Flu-MP specific T cells—in all
three individuals who were tested (Fig. 6, B and C).
One of the patients (K2) received an inactivated influ-
enza vaccine as a part of routine care, shortly after the injec-
tion of  -GalCer–loaded DCs. Traditionally, these vaccines
are believed to be poor at activating CD8  killer T cell re-
sponses and mostly boost only humoral immunity (34). Sur-
prisingly, there was a significant expansion of Flu-MP–spe-
cific, IFN- –producing, and memory T cells in this patient
which was consistent with enhancement of vaccine-induced
immune response with  -GalCer–pulsed DCs (Fig. 6 D).
Expansion/activation of NK cells
Activation of NKT cells in mice can lead to rapid activation
of NK cells in vivo (35). DCs also can lead directly to activa-
tion of innate effectors, including NK cells (36). We ob-
Figure 4. Function of freshly isolated NKT cells mobilized in vivo. 
(A) Intracellular cytokine staining for  -GalCer reactive IFN-  production. 
Freshly isolated PBMCs from postvaccination samples (K2–K5) containing 
NKT cells or healthy donors (H1–H5) were cultured overnight with anti-
CD28 alone (as control [Ctrl]), or with 100 ng/ml  -GalCer ( GC) in the 
presence of monensin. The percentage of IFN- –producing V 24 V 11  
cells was quantified by flow cytometry. The data shown are gated on 
V 24 V 11  cells. (B) Detection of  -GalCer reactive IFN- –producing 
cells by Elispot. Freshly isolated PBMCs from pre- or postvaccination 
samples were cultured overnight with 100 ng/ml  -GalCer. The presence 
of IFN- –producing cells was quantified by ELISPOT.DC-MEDIATED NKT ACTIVATION IN CANCER | Chang et al. 1510
Figure 5. Proliferative capacity and function of mobilized NKT 
cells. (A) DC-mediated expansion of mobilized NKT cells in vitro. Pre- 
and postimmunization PBMCs were thawed together and cultured with 
autologous monocyte-derived mature DCs with or without pulsing with 
100 ng/ml  -GalCer ([ GC]; DC/responder ratio of 1:20), in the presence 
of 50 U/ml IL-2. After 7 d of culture, the presence of V 24 /V 11  
invariant NKT cells was quantified by flow cytometry. Numbers in the 
quadrant indicates the percentage of cells in the quadrant of the total 
lymphocyte population. (B) Binding of iNKT cells expanded in vitro from 
postvaccine samples to CD1d– -GalCer dimers. Dimer( ) refers to un-
loaded dimers. Expression of V 24 or V 11 on dimer-binding cells was 
analyzed by flow cytometry. (C) IFN-  production by ex vivo expanded 
NKT cells. NKT cells expanded ex vivo as in (A) were stimulated overnight 
with unpulsed or  -GalCer–pulsed autologous DCs in the presence of 
monensin. NKT cells expanded from healthy donors (H6–H8) were used 
as a control. The presence of IFN- –producing cells was quantified by 
flow cytometry. (D) TaqMan analysis of cytokine secretion in expanded 
NKT cells. NKT cells expanded ex vivo as in (A) were stimulated overnight 
with unpulsed or  -GalCer–pulsed autologous DCs. NKT cells expanded 
from healthy donors (H9–H11) were used as a control. The presence of 
mRNA for selected cytokines (IFN- , IL-4, IL-10, and IL-13) was ana-
lyzed by real time RT-PCR. Data were normalized to the expression of a 
housekeeping gene, GAPDH.  -GalCer reactive transcription was ana-
lyzed by comparing the expression in control versus  -GalCer–stimulated 
samples. *P   0.05 for comparison with healthy donor control.JEM VOL. 201, May 2, 2005 1511
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Figure 5 (continued)
served a mild transient decline in circulating NK cell num-
bers at 6 h or 24 h after all vaccines. The cause of this decline
is not known, but it did not differ between unpulsed or
 -GalCer–pulsed DCs. In two patients (K2 and K3), there
was a transient spike in NK numbers (and CD16  and
CD16 CD56high subsets) after  -GalCer–pulsed DCs. How-
ever, this was within the interassay variance that was seen at
baseline (Fig. 7). There was no detectable up-regulation of
CD69 on NK cells/subsets, and no changes in the expression
of natural cytotoxicity receptors p30, p44, and p46 on NK
cells/subsets after DC vaccination (unpublished data). There
also was no detectable increase in IFN-  production in the
CD3 population that was enriched in NK cells after vaccina-
tion. These studies only monitored blood NK cells; further
analysis of changes in NK cell function, particularly in lym-
phoid tissues, is needed to assess fully the impact of DC vac-
cines on NK cells in vivo in humans (37).
DISCUSSION
These data reveal that the injection of  -GalCer–pulsed ma-
ture DCs can lead to sustained expansion of glycolipid-reac-
tive NKT cells in vivo in humans. The NKT expansion that
was induced by only two injections of  -GalCer–loaded ma-
ture DCs lasted for several months. This is in contrast with the
reported transient NKT activation that was observed in re-
sponse to KRN-7000 alone, or pulsed on immature DCs (20,
21). NKT cells expanded in all patients we studied, even
though these patients had severe NKT deficiencies at baseline,
and the patients were not preselected based on a minimum
NKT cutoff, as in earlier studies (21). NKT expansion was
feasible in vivo, even when NKT cells could not be expanded
in vitro from the preimmunization samples of these patients.
Therefore, as with peptide antigens, targeting glycolipid anti-
gens to mature DCs leads to enhanced immune activation.
The feasibility of a sustained expansion of NKT cells pro-
vides the opportunity to study the biology of mobilized hu-
man glycolipid-reactive T cells in vivo. Recent studies have
shown that human NKT cells can be divided into distinct sub-
sets (CD4 , double negative, CD8 ) with distinct functional
properties (25, 26). Our data show that all three subsets can be
expanded with DCs that are loaded with  -GalCer in vivo.
However, at least in some patients, we observed that the pro-
portions of these subsets changed over time, which suggests
different kinetics of mobilization, tissue homing, or survival.
Additional patients will need to be studied to characterize this
further. A similar kinetics of different NKT subsets recently
were observed after in vitro expansion (38). Also, it is now
clear that the repertoire of glycolipid-reactive T cells—as de-
tected using glycolipid-CD1d multimers—includes standard
invariant TCR ve and TCR ve cells (24). In this study, we
also observed an expansion of V 24 CD1d dimer  cells; this
suggests that both populations of glycolipid-reactive T cells are
expanded in vivo with this ligand.
Activation of NKT cells by  -GalCer in vivo leads to
rapid release of cytokines and activation of other immune ef-
fectors. Recent studies in mice suggest that  -GalCer–medi-
ated NKT activation can provide an adjuvant function, and
enhance T cell immunity to coadministered antigen, whichDC-MEDIATED NKT ACTIVATION IN CANCER | Chang et al. 1512
Figure 6. Changes in antigen-specific T cell responses. (A) Changes 
in CMVpp65  and Flu-MP–specific IFN- –producing T cells. Freshly 
isolated PBMCs were cultured overnight with defined A2-restricted 
peptides from Flu-MP or CMVpp65. The number of antigen-specific 
IFN- –producing T cells was measured using an Elispot assay. (B) Ex-
pansion of virus-specific memory T cells (recall tetramer assay). Samples 
from pre- or postimmunization samples were thawed together and 
cocultured with autologous mature DCs that were pulsed with specific 
peptides. After 7 d of culture, the number of peptide-specific MHC 
tetramer binding T cells was quantified by flow cytometry. (C) Repre-
sentative FACS plots showing staining for CMVpp65-HLA A2 tetramer 
and Flu-MP–A2 tetramer, from an expansion as in (B). Number indicates 
percent of tetramer positive cells in the quadrant. (D) Changes in Flu-MP–
specific memory T cells in a patient who also received an inactivated 
influenza vaccine during the course of the trial. Pre- and postimmuni-
zation T cells were thawed together and expanded with autologous 
peptide-pulsed DCs as in (B). After 7 d of culture, the presence of 
Flu-MP–A2 tetramer binding T cells was monitored by flow cytometry. 
SFC, spot-forming cells.JEM VOL. 201, May 2, 2005 1513
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is mediated by induction of DC maturation (31–33). In this
study, NKT activation was associated consistently with a
transient loss of circulating NKT cells and an increase in the
serum levels of IP-10, IL-12 p40, and MIP-1 . Generally,
these cytokines are believed to be derived from myeloid
APCs. Therefore, these data are consistent with the possibil-
ity that NKT activation led to downstream activation of my-
eloid antigen-presenting DCs in vivo.
The activation of NKT cells also was associated with an
expansion of antigen-specific memory T cells, as might be
expected if the DCs that matured in vivo in response to
NKT cells also were capturing antigens (31–33). Changes in
antigen-specific T cell function were not tested in earlier
clinical studies that targeted NKT cells via  -GalCer. The
increase in memory T cells was observed only for those for
which the antigen was persistent (CMV), but not for influ-
enza, for which the antigen is lacking. The only setting in
which a clear increase in Flu-MP–specific memory T cells
was observed was after concurrent injection of an influenza
vaccine in one patient. These data do not allow us to estab-
lish a causal relationship between NKT and T cell activation,
but suggest a correlation. In previous studies of DC immu-
notherapy, we and others had not observed a nonspecific in-
crease in virus-specific memory T cells (39). Therefore, we
believe that this likely is due to the inclusion of KRN-7000
as an adjuvant with the DCs. However, these data do not
distinguish between direct effects of NKT cells on APCs and
indirect effects via release of cytokines. In view of these find-
ings, the breadth of T cell analysis in future NKT-based hu-
man trials needs to be extended.
In recent studies, NKT cells from myeloma and other ad-
vanced cancers were defective in their ability to secrete IFN- 
after  -GalCer stimulation in vitro (17, 19). The circulat-
ing NKT cells that were mobilized in this trial had similar de-
fects in their ability to secrete IFN-  in vitro, when com-
pared with those that were isolated from healthy donors. This
was true even after these cells were expanded in culture using
 -GalCer–loaded DCs. One possibility is that NKT cells in
blood may be distinct from those in the tissues (40). The
mechanism behind the paucity of IFN-  secretion by circu-
lating NKT cells in cancer is not known, but may relate to
the effects of suppressor cytokines or to binding of self- or tu-
mor-derived CD1d ligands in vivo (41–43). Understanding
the mechanism of loss of NKT effector function and pharma-
cologic restoration of this function in vivo might improve the
clinical efficacy of NKT targeting against human cancers.
In this trial, we observed a rapid, but transient, decline in
circulating NK cell numbers after each DC vaccine. How-
ever, this was similar between unpulsed and KRN-7000–
pulsed DCs, and therefore, could not be ascribed to KRN-
7000. The cause for this decline in NK cells is not known.
However, it is consistent with the recent observations of
Martin-Fontecha and colleagues of DC-mediated transient
NK recruitment to lymphoid tissues in mice (37), and had
not been tested previously in human DC vaccine studies
(44). This loss of NK cells from the blood also may have
limited our ability to detect NKT-mediated NK activation,
because we are unable to access NK cells in lymphoid tissues
or spleen at these time points in the human setting.
In summary, these data provide evidence that the presen-
tation of  -GalCer by mature DCs allows reliable and sus-
tained expansion of glycolipid-reactive NKT cells in vivo in
humans. Given the importance of NKT cells in microbial
and tumor immunity,  -GalCer–pulsed DCs may be a useful
clinical therapeutic approach for targeted immune restora-
tion of NKT cells, analogous to the current use of granulo-
Figure 7. Changes in NK cells. The number of CD3 CD56  NK cells in fresh PBMCs was monitored by flow cytometry, before and after DC vaccination.DC-MEDIATED NKT ACTIVATION IN CANCER | Chang et al. 1514
cyte colony-stimulating factors for boosting neutrophils in
humans. The lack of NKT expansion with unpulsed DCs
was somewhat surprising, because they would be expected
to present endogenous NKT ligands. These data suggest that
this time-consuming control may be omitted in future stud-
ies. DC-mediated human NKT activation also leads to
downstream DC activation and enhanced memory T cell
function in vivo. Defects in DC maturation have been pro-
posed to underlie immune paralysis in cancer and HIV infec-
tion (45, 46). Therefore, NKT cell–mediated DC activation
in vivo may be an approach to help alleviate cancer-associ-
ated immune paresis. Enhancement of T cell memory also
may be of benefit in patients who have persistent viral infec-
tions, such as HIV or hepatitis. The data also provide a
framework for combining this approach with other vaccines
that target T cells, particularly against tumors and chronic vi-
ral infections. Further study of this approach in larger num-
bers of patients is needed to better understand the impact of
interindividual variability in NKT cells on the efficacy of
NKT targeting in humans. In our view, such studies will re-
quire the use of cryopreserved DCs that are generated from
progenitors using closed systems. Earlier studies for harness-
ing the adjuvant function of DCs in humans focused solely
on directly activating T cell immunity via loading antigens
on DCs that were generated ex vivo (44); however, the ex-
periments reported here show that DCs can be effective ad-
juvants for boosting innate effectors in humans as well, and
that this can lead to an increase in adaptive immunity to an-
tigens that are being presented in vivo in the treated patients.
MATERIALS AND METHODS
Study design and eligibility. The study design was a single-arm open-
label trial to test the feasibility and tolerability of injection of unpulsed and
KRN-7000–pulsed DCs in patients who had advanced cancer (Fig. 8). Pa-
tients who had relapsed or persistent myeloma after initial therapy, meta-
static renal cell cancer, unresectable or metastatic hepatocellular cancer, or
metastatic cancer of any histologic type that had failed standard therapy
were eligible. Other eligibility criteria were: Eastern Cooperative Oncology
Group performance score of 0–2, age  18 yr, and adequate organ function
(hemoglobin  8 g/dl, white blood cells  3,000/ l, serum transaminases
 4  upper normal limits, and serum bilirubin  3 mg/dl). Patients who
had active or chronic infections, known clinical autoimmune disease, or
Gaucher’s disease, and pregnant or lactating females were excluded. All pa-
tients signed an informed consent that was approved by the Rockefeller
University Institutional Review Board, and the study was conducted under
an Investigational New Drug application that was approved by the U.S.
Food and Drug Administration.
Treatment and monitoring schema. After screening and registration,
patients underwent a 2–3 h steady-state leukapheresis for the collection of
DC progenitors. All patients received an initial intravenous injection of 5
million unpulsed monocyte-derived mature DCs, followed at monthly in-
tervals by two additional injections of mature DCs that were pulsed with
 -GalCer (KRN-7000). Unpulsed DCs were injected as a control because
of the possibility that mature DCs alone might stimulate NKT cells in vivo
(47). After each injection, patients were observed overnight at the Rock-
efeller University General Clinical Research Center. Patients were evalu-
ated at 4 and 7 d after each injection, 30 d after the last injection, and every
3 mo thereafter, until removal from the study. Complete blood count and
serum chemistries, including liver function tests, were monitored at base-
line, 1 d, 7 d, and 1 mo after each injection. Patients also were monitored
for the development of RF or ANAs.
Generation of DCs. DCs were generated from blood monocytes using a
protocol that was adapted from Thurner et al., in a dedicated facility under
good tissue practices guidelines (48). In brief, mononuclear cells were iso-
lated from leukapheresis specimens using Ficoll Hypaque density gradient
centrifugation and cryopreserved in aliquots. For generating DCs, the
mononuclear cells were thawed and allowed to adhere in tissue culture
plates. Adherent monocytes were cultured in RPMI 1640 (Biowhittaker)
supplemented with 1% autologous plasma, in the presence of 20 ng/ml
GM-CSF (Immunex) and 20 ng/ml IL-4 (Cell Genix). The cultures were
supplemented with cytokines on days 1, 3, and 5 of culture. On day 5, im-
mature DCs were transferred to fresh six-well plates, and induced to ma-
ture using an inflammatory cytokine cocktail that consisted of 10 ng/ml
IL-1 , 1,000 U/ml IL-6, 10 ng/ml TNF-  (all obtained from Cell Genix),
and 1  g/ml prostaglandin E2 (Amersham Biosciences). This maturation
stimulus was chosen based on preclinical data which showed that matura-
tion cytokines were comparable to other stimuli, such as CD40 ligand or
LPS (29), and because it yields a uniform population of phenotypically ma-
ture DCs. For KRN-7000 loading, DCs were pulsed with 100 ng/ml of
KRN-7000 at the time of DC maturation. The DCs were harvested for in-
jection  20 h after the induction of maturation, and reconstituted in 5%
autologous plasma in normal saline at 1 million DCs/ml before intravenous
injection. Release criteria for DCs were viability  80%, purity  50%, ma-
turity (expressed as percentage of CD83  cells)  60%, negative gram stain,
endotoxin and mycoplasma PCR, and negative in process cultures from
samples sent 48 h before release. Postrelease tests included negative ex-
tended sterility cultures, and mycoplasma PCR. DC preparations also were
monitored for the ability to stimulate allogeneic mixed lymphocyte reac-
tions. Effective loading of the final product with  -GalCer was monitored
by testing the ability of these DCs to expand NKT cells in culture, without
further ex vivo loading. All products met all release criteria and postrelease
testing, and the DCs had a typical phenotype of CD14 , HLA DR , and
CD83  cells (48).
Immunologic monitoring. Immune monitoring was performed pre-
dominantly using blood samples. In all patients, at least three baseline sam-
ples were obtained before the first injection in order to establish a baseline.
Follow-up samples for immune monitoring were obtained at 6 h, 24 h, 4 d,
7 d, and 1 mo after each DC injection, and every 3 mo after the last injec-
tion. When possible, samples of bone marrow aspirates in myeloma patients
were used to assess the changes in NKT cells in the tumor bed before and
after vaccination.
Number and subsets of NKT cells. The numbers of NKT cells in
freshly isolated blood or bone marrow mononuclear cells were quantified
by multi-parameter flow cytometry, based on the expression of invariant T
cell receptor (V 24/V 11) on the cell surface and intracellularly after per-
meabilization using saponin, and binding to CD1d dimer (DimerX, BD
Biosciences) loaded with  -GalCer using the manufacturer’s recommenda-
tions. At least 2   105 lymphocyte-gated events were acquired to allow re-
liable estimation of NKT cells. Subsets of expanded NKT cells were moni-
tored based on the expression of CD4 or CD8 on invariant T cell receptor
positive cells. Figure 8. Schema for clinical trial.JEM VOL. 201, May 2, 2005 1515
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Functional studies on NKT cells. Functional aspects of NKT cells were
assayed based on cytokine production and proliferation in response to
 -GalCer. Cytokine production was measured in fresh PBMCs and after in
vitro expansion using  -GalCer–loaded DCs, and analyzed by Elispot, in-
tracellular cytokine flow cytometry, quantitative RT-PCR by TaqMan,
and multiplex cytokine analysis.
Stimulation of NKT cells in culture. To assess the ability of NKT cells
to proliferate in culture, pre- and postimmunization PBMCs were thawed to-
gether and cultured in the presence of autologous  -GalCer–pulsed mono-
cyte-derived mature DCs (on unpulsed DCs as a control), at a DC/PBMC
ratio of 1:20 in the presence of 50 U/ml of IL-2 (Chiron), as described (19,
22). Expansion of NKT cells was monitored by quantifying V 24 /V 11 
or CD1d   -GalCer dimerX-binding NKT cells by flow cytometry.
Elispot assay for IFN- –producing T/NKT cells. To detect IFN- –
producing NKT cells, freshly isolated PBMCs (5   105 cells/well) were
cultured overnight in the presence of 100 ng/ml  -GalCer in Elispot plates
that were precoated with anti–IFN-  antibody (Mabtech), as described
(19). For detecting influenza-specific T cells, PBMCs were infected with
influenza (MOI   2) before plating in the Elispot assay. Staphylococcal en-
terotoxin A (50 ng/ml was used as a positive control. In HLA A2  patients,
antigen-specific T cells against A2-restricted peptides from influenza matrix
protein and CMVpp65 also were monitored using this assay, as described
previously (49).
Intracellular cytokine detection by flow cytometry. For the detec-
tion of ICS, freshly isolated PBMCs were cultured overnight with 100 ng/
ml  -GalCer in the presence of anti-CD28 (3  g/ml; BD Biosciences), or
anti-CD28 alone as a control in the presence of 0.7  g/ml Golgi Stop
(from Cytofix/Cytoperm Plus kit from BD Biosciences). Stimulation with
PMA (50 ng/ml) and ionomycin (1  M) was used as positive control. The
presence of IFN- –producing V 24 /V 11  cells was quantified by flow
cytometry, as described (19). For the detection of intracellular cytokine pro-
duction by expanded NKT cells (after 1-wk culture with DCs as described
above; recall ICS), these cells were restimulated overnight with unpulsed or
 -GalCer–loaded DCs (DC/responder ratio 1:10), before staining and anal-
ysis, as described (19).
TaqMan RT-PCR quantitation of mRNA. Analysis of  -GalCer–reac-
tive cytokine production in the Elispot and ICS assays was limited to IFN- .
Therefore, we used cytokine multiplex analysis and TaqMan RT-PCR to
assay the production of alternate cytokines in these cultures. For the TaqMan
analysis, PBMCs were cultured with  -GalCer as described earlier. For some
assays, pre- and postimmunization samples expanded with DCs were restim-
ulated with unpulsed or  -GalCer–loaded DCs (DC/responder ratio of
1:10) for 8 h. Stimulated cells were pelleted and total RNA was isolated us-
ing the QIAGEN RNeasy kit. The primers and probes for IFN- , and IL-4,
-10, and -13 were purchased from Applied Biosystems/PerkinElmer. RT-
PCR reactions were performed in duplicate samples according to the manu-
facturer’s directions (EZ PCR Core Reagents; TaqMan and Applied Bio-
systems), using an Applied Biosystems PRISM 7700 Thermal cycler, as
described previously (50). mRNA levels for a housekeeping gene GAPDH
were used to normalize each gene from each sample.
Cytokine multiplex analysis. Serum was analyzed for 20 cytokines and
chemokines using the Protein Multiplex Immunoassay kit (Biosource Inter-
national) as per the manufacturer’s protocol. Briefly, Biosource’s Multiplex
beads were vortexed and sonicated for 30 s and 25  l was added to each
well and washed twice with wash buffer. The samples were diluted 1:2 with
assay diluent and loaded onto a Millipore Multiscreen BV 96-well filter
plate; 50  l of incubation buffer had been added previously to each well.
Serial dilutions of cytokine standards were prepared in parallel and added to
the plate. Samples were incubated on a plate shaker at 600 revolutions/min
in the dark at room temperature for 2 h. The plate was applied to a Milli-
pore Multiscreen Vacuum Manifold and washed twice with 200  l of wash
buffer. 100  l of biotinylated Anti-Human Multi-Cytokine Reporter was
added to each well. The plate was incubated on a plate shaker at 600 revo-
lutions/min in the dark at room temperature for 1 h. The plate was applied
to a Millipore Multiscreen Vacuum Manifold and washed twice with 200
 l of wash buffer. Streptavidin-phycoerythrin was diluted 1:10 in wash
buffer, and 100  l was added directly to each well. The plate was incubated
on a plate shaker at 600 revolutions/min in the dark at room temperature
for 30 min. The plate was applied to the vacuum manifold, washed twice,
and each well was resuspended in 100  l wash buffer and shaken for 1 min.
The assay plate was transferred to the Bio-Plex Luminex 100 XYP instru-
ment for analysis. Cytokine concentrations were calculated using Bio-Plex
Manager 3.0 software with a five parameter curve-fitting algorithm applied
for standard curve calculations.
Analysis of NK cell subsets and activation. The numbers of NK cells
and their subsets (CD16neg CD56hi; CD16pos CD56lo) in blood mononu-
clear cells before and after vaccination were monitored by flow cytometry.
The activation status of NK cells was monitored based on the expression of
CD69 and natural cytotoxicity receptors (p30, p44, and p46).
Analysis of antigen-specific T cell responses. Influenza virus–specific
T cells were monitored by Elispot and intracellular cytokine staining, as de-
scribed earlier (19). In HLA-A2  patients, T cell responses to A2-restricted
epitopes that were derived from influenza matrix protein and CMVpp65
were monitored by ELISPOT in fresh PBMCs. Antigen-specific T cells
against these epitopes also were quantified by MHC tetramers, as described
(39). To assess the ability of memory T cells to proliferate in culture, pre-
and postimmunization samples were thawed and cultured with peptide-
pulsed DCs, as described previously (39). After 1 wk of culture, antigen-
specific CD8  T cells were quantified using MHC tetramers.
Statistical analysis. Data from pre- and postimmunization assays were
compared using the Student’s t test, or Mann-Whitney test. Significance
was set at P   0.05.
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